PF-06252616: Phase II started

Pfizer began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 5, 20 and 40 mg/kg IV PF-06252616 in about 105 patients ages 6-9. The compound has Orphan Drug designation in the U.S. ...